IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1226-1250 out of 1352.

<< < 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 > >>

Public Release: 21-Jan-2016
Screening gets top marks for picking up bowel cancer early
Bowel cancer is more likely to be diagnosed at the earliest stage if it is picked up by screening, according to new figures released by Cancer Research UK and Public Health England's National Cancer Intelligence Network today.
Cancer Research UK, Public Health England

Contact: Paul Thorne
paul.thorne@cancer.org.uk
44-203-469-8352
Cancer Research UK

Public Release: 21-Jan-2016
JAMA Oncology
Nonrecommended screenings for prostate, breast cancer in older individuals
An estimated 15.7 percent of individuals 65 or older may have received nonrecommended screenings for prostate and breast cancers because they had limited life expectancies of less than 10 years, according to an article published online by JAMA Oncology.

Contact: Tammy Battaglia
Tammy.Battaglia@hfhs.org
248-881-0809
The JAMA Network Journals

Public Release: 21-Jan-2016
Cell Chemical Biology
Glowing tumors could help surgeons cut out cancer
Optical probes that light up cancer cells, which are meant to improve tumor removal, are already in phase I and phase II clinical trials in humans and could be a common procedure in the next 5-10 years. A review of their progress is published Jan. 21 in the premier issue of Cell Chemical Biology, previously known as Chemistry & Biology.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 21-Jan-2016
JAMA Oncology
Study examines associations of HPV types, risk of head and neck
A new study suggests detection of human papillomavirus (HPV)-16 in the oral cavity was associated with 22-times increased risk of oropharyngeal squamous cell carcinoma.

Contact: Deirdre Branley
dbranley@einstein.yu.edu
718-430-2923
The JAMA Network Journals

Public Release: 21-Jan-2016
JAMA Oncology
Study examines link between HPV and risk of head and neck cancers
Researchers, led by Ilir Agalliu, M.D., and Robert Burk, M.D., at Albert Einstein College of Medicine have found that when human papillomavirus (HPV)-16 is detected in peoples' mouths, they are 22 times more likely than those without HPV-16 to develop a common type of head and neck cancer.

Contact: Cindy Miller
cindy@winukpr.com
973-420-1605
Albert Einstein College of Medicine

Public Release: 20-Jan-2016
Nature Reviews Clinical Oncology
Up to 50 percent of women with advanced-stage ovarian cancer could be cured with 1 treatment model
Up to half of women with advanced-stage ovarian cancer might be cured, compared to the current 20 percent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late-stage ovarian cancer.

Contact: Magda Stec
magda.stec@wchospital.ca
416-323-6400 x3210
Women's College Hospital

Public Release: 20-Jan-2016
Nature Communications
Study results leading to the development of a new type of anticancer agent
A wide variety of research has shown that γ-tubulin activates during cell division and that it is overexpressed in a portion of cancer cells, so it holds potential as a target protein for new anticancer agents with few side effects. Despite this research, no specific inhibitors have thus far been discovered.
Ministry of Education, Culture, Sports, Science and Technology, Platform for Drug Discovery, Informatics and Structural Life Science, Japan Society for the Promotion of Science

Contact: Masataka Watanabe
kohositu@un.tsukuba.ac.jp
81-298-532-039
University of Tsukuba

Public Release: 20-Jan-2016
PLOS ONE
Small but deadly: The chemical warfare of sea slugs
Brightly colored sea slugs are slurping deadly chemicals and stockpiling the most toxic compounds for use on their enemies. While the phenomenon sounds like the stuff of horror films, it is common practice for these "butterflies of the ocean", a new University of Queensland-led study published today in PLOS One has found.
Australian and Pacific Science Foundation, Australian Research Council (ARC), University of Queensland, Australian Government Postgraduate Endeavour Award, Mexican Council for Science and Technology

Contact: Karen Cheney
k.cheney@uq.edu.au
61-733-657-386
University of Queensland

Public Release: 20-Jan-2016
Journal of American Chemical Society
Using light for targeted drug delivery could help fight tumors, local infections
Some drug regimens, such as those designed to eliminate tumors, are notorious for nasty side effects. Unwanted symptoms are often the result of medicine going where it's not needed and harming healthy cells. To minimize this risk, researchers have developed nanoparticles that only release a drug when exposed to near-infrared light, which doctors could beam onto a specific site. Their report appears in the Journal of the American Chemical Society.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 20-Jan-2016
Journal of American College of Surgeons
NCDB study results define optimal waiting time before surgery following chemoradiotherapy
Researchers analyzing data from the National Cancer Data Base (NCDB) have found that patients who had a cancer operation at precisely eight weeks -- 56 days -- after the end of combined chemoradiotherapy had the best overall survival and successful removal of their residual tumors.

Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
American College of Surgeons

Public Release: 20-Jan-2016
Journal of the American Academy of Dermatology
Cleveland clinic finds pregnancy-associated melanoma is associated with higher death rates
Melanoma, the deadliest form of skin cancer, is on the rise in women of child-bearing age. Those at the greatest risk, according to new Cleveland Clinic research, are women younger than 50 who are pregnant or have recently been pregnant.

Contact: Kelsey Buller
bullerk@ccf.org
216-409-6715
Cleveland Clinic

Public Release: 20-Jan-2016
New England Journal of Medicine
Biomarker predicts which stage II colon cancer patients may benefit from chemotherapy
Researchers from Columbia, Stanford, UC-Davis, and other institutions have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
National Institutes of Health

Contact: Karin Eskenazi
ket2116@columbia.edu
212-342-0508
Columbia University Medical Center

Public Release: 20-Jan-2016
eLife
Researchers pinpoint place where cancer cells may begin
In a study involving the fruit fly equivalent of an oncogene implicated in many human leukemias, a Northwestern University research team has gained insight into how developing cells normally switch to a restricted, or specialized, state and how that process might go wrong in cancer. The researchers were surprised to discover that levels of an important protein start fluctuating wildly in cells during this transition period. If the levels don't or can't fluctuate, the cell doesn't switch and move forward.
US Department of Energy, National Institutes of Health

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University

Public Release: 20-Jan-2016
New England Journal of Medicine
New biomarker identifies colon cancer patients who may benefit from chemotherapy
Using a new computer science approach, researchers at University of California, San Diego School of Medicine, Columbia University and Stanford University discovered a distinctive molecular feature -- a biomarker -- that identified colon cancer patients who were most likely to remain disease-free up to five years after surgery. The biomarker, a protein called CDX2, also helped the researchers identify Stage II colon cancer patients who are most likely to benefit from chemotherapy after surgery.
National Comprehensive Cancer Network, National Institutes of Health, Siebel Stem Cell Institute, Thomas and Stacey Siebel Foundation, Virginia and D.K. Ludwig Fund for Cancer Research, California Institute for Regenerative Medicine

Contact: Heather Buschman
hbuschman@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 20-Jan-2016
Nature Methods
GenomeSpace 'recipes' help biologists interpret genomic data
Researchers at University of California, San Diego School of Medicine and collaborators developed GenomeSpace, a cloud-based, biologist-friendly platform that connects more than 20 bioinformatics software packages and resources for genomic data analysis. The team is now developing and crowdsourcing 'recipes' -- step-by-step workflows -- to better enable non-programming researchers to interpret their genomic data. The work is described in a paper published Jan. 18, 2016 in Nature Methods.
NIH/National Human Genome Research Institute, Amazon Web Services

Contact: Heather Buschman
hbuschman@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 20-Jan-2016
Clinical Cancer Research
Inherited genetic markers may predict melanoma survival -- and help plot course of disease
How long will a patient survive following the removal of a melanoma tumor? A more definitive answer to that question could come from new studies at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual's survival and determine which patients require closer monitoring in the years following surgery.
NIH/National Cancer Institute

Contact: Jim Mandler
jim.mandler@nyumc.org
212-404-3525
NYU Langone Medical Center / New York University School of Medicine

Public Release: 19-Jan-2016
JAMA
Researchers advocate improvements in end-of-life care
Three Dana-Farber Cancer Institute researchers, writing in a special issue of JAMA published today, make the case for policies and practices that give terminally ill patients more control over how and where they will die.

Contact: Anne Doerr
anne_doerr@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute

Public Release: 19-Jan-2016
American Journal of Obstetrics and Gynecology
A new method to improve the pre-operative diagnosis of ovarian cancer based on ultrasound
In a landmark study, investigators from Europe propose a new and simple method to assess the risk of malignancy of women with an adnexal mass. The method identified between 89-99 percent of patients with ovarian cancer using the results of ultrasound examination, which can be obtained in referral and non-referral centers. The work is based on the 'Simple Rules' criteria developed by the International Ovarian Tumor Analysis group to improve accurate diagnosis of ovarian cancer before surgery.

Contact: Eileen Leahy
ajogmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 19-Jan-2016
American Journal of Obstetrics and Gynecology
Fine-tuned test predicts risk of ovarian cancer with great precision
Researchers from KU Leuven, Belgium, have improved a test for ultrasound diagnosis of ovarian tumors. Professors Dirk Timmerman and Ben Van Calster collaborated with scientists from Imperial College London and Lund University.

Contact: Dirk Timmerman
dirk.timmerman@med.kuleuven.be
32-163-44201
KU Leuven

Public Release: 19-Jan-2016
Cancer Research
New target identified for reducing cancer metastasis
A protein that is constantly expressed by cancer cells and quiescent in healthy ones appears to be a solid target for reducing cancer's ability to spread, scientists report.
NIH/National Cancer Institute

Contact: Toni Baker
tbaker@gru.edu
706-721-4421
Medical College of Georgia at Augusta University

Public Release: 19-Jan-2016
CA: A Cancer Journal for Clinicians
New precision medicine guidelines aimed at improving personalized cancer treatment plans
A committee of national experts, led by a Cleveland Clinic researcher, has established first-of-its-kind guidelines to promote more accurate and individualized cancer predictions, guiding more precise treatment and leading to improved patient survival rates and outcomes.

Contact: Laura Ambro
ambrol@ccf.org
216-636-5876
Cleveland Clinic

Public Release: 19-Jan-2016
Diabetes Technology & Therapeutics
Advances in continuous glucose monitoring technology will pave the way to an artificial pancreas
As the accuracy, reliability, adoption, and successful use of Continuous Glucose Monitoring continue to increase, the ultimate goal of combining CGM with an insulin pump and sophisticated algorithms for automating the control and suspension of insulin infusion -- known as the 'artificial pancreas' -- moves closer to becoming a reality.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 19-Jan-2016
Proceedings of the National Academy of Sciences
Disrupting cell's supply chain freezes cancer virus
The cancer-causing Epstein-Barr virus tricks B-Cells of the human immune system into rapid cell division. To satisfy demand for more building parts, host cells will chew up their insides to free up more amino acids, fats and nucleotides. The virus also switches the cell's source of fuel to keep division going. A Duke team finds that cutting off the supply chain puts the cell in a suspended state, freezing the advance of the virus.
National Institutes of Health, Duke Center for AIDS Research

Contact: Karl Leif Bates
karl.bates@duke.edu
919-681-8054
Duke University

Public Release: 19-Jan-2016
British Journal of Surgery
Delirium is common in older gastrointestinal surgery patients
A new analysis indicates that delirium commonly develops in the older patients who have undergone gastrointestinal surgery. Among 11 studies analyzed, the incidence of postoperative delirium ranged from 8.2 to 54.4 percent.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 19-Jan-2016
Nature Nanotechnology
Nanoparticles combine photodynamic and molecular therapies against pancreatic cancer
A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity.
National Institutes of Health

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Showing releases 1226-1250 out of 1352.

<< < 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 > >>

  Search News Releases

     

 

EurekAlert!